← The Klinique Med Clinic PCL overview

The Klinique Med Clinic PCL vs Meituan: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Klinique Med Clinic PCL (KLINIQ.BK)

Q3 2026
▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

  • Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.

    This is the core new event that resets growth expectations for the year.

  • Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.

    Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.

  • Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.

    Dividend news is a new, concrete return of cash to shareholders that supports the price.

  • Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.

    It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

August 2026
▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

  • Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.

    This is the core new event that resets growth expectations for the year.

  • Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.

    Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.

  • Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.

    Dividend news is a new, concrete return of cash to shareholders that supports the price.

  • Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.

    It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

Latest
▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

  • Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.

    This is the core new event that resets growth expectations for the year.

  • Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.

    Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.

  • Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.

    Dividend news is a new, concrete return of cash to shareholders that supports the price.

  • Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.

    It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

Meituan (3690.HK)

Q3 2026
▲2▼2

Meituan's subsidy war cools as Q2 profit returns, but Alibaba and JD keep fighting

  • New subsidy rules curb the cash-burning delivery war China's market regulator proposed 10 rules banning prolonged, large-scale subsidy wars in food delivery. Meituan has burned huge cash defending its share, so less forced discounting should improve its long-term profit per order, even though the shares dipped on the day.

    Regulation directly changes the competitive economics that have crushed Meituan's margins.

  • Alibaba bids $1.5B for Pupu, reigniting grocery-delivery rivalry Alibaba offered $1.5 billion for grocery delivery firm Pupu, months after Meituan agreed to buy Dingdong Fresh for $717 million. The bidding war shows rivals are again spending to win market share rather than protect profits, which pressures Meituan to keep investing.

    A direct competitive escalation that could reverse the profit-friendly subsidy truce.

  • JD.com stays aggressive in delivery despite calmer fight JD beat profit estimates as its food delivery losses narrowed, and still targets 30% of the instant-delivery market by year-end, double its starting share. Even with regulators warning against aggressive competition, JD's expansion keeps pressure on Meituan's share and pricing.

    Shows the competitive threat is structural, not fading, even as JD's losses shrink.

  • Record Q2 revenue and return to core profitability Meituan posted record quarterly revenue of RMB104.6 billion, up 14.4%, with adjusted net profit of RMB2.5 billion and core local commerce back in profit. It holds RMB168.3 billion cash and may sell investments worth over RMB70 billion to fund growth and returns.

    The clearest evidence yet that Meituan's core business can make money again.

July 2026
▲2▼2

Meituan's subsidy war cools as Q2 profit returns, but Alibaba and JD keep fighting

  • New subsidy rules curb the cash-burning delivery war China's market regulator proposed 10 rules banning prolonged, large-scale subsidy wars in food delivery. Meituan has burned huge cash defending its share, so less forced discounting should improve its long-term profit per order, even though the shares dipped on the day.

    Regulation directly changes the competitive economics that have crushed Meituan's margins.

  • Alibaba bids $1.5B for Pupu, reigniting grocery-delivery rivalry Alibaba offered $1.5 billion for grocery delivery firm Pupu, months after Meituan agreed to buy Dingdong Fresh for $717 million. The bidding war shows rivals are again spending to win market share rather than protect profits, which pressures Meituan to keep investing.

    A direct competitive escalation that could reverse the profit-friendly subsidy truce.

  • JD.com stays aggressive in delivery despite calmer fight JD beat profit estimates as its food delivery losses narrowed, and still targets 30% of the instant-delivery market by year-end, double its starting share. Even with regulators warning against aggressive competition, JD's expansion keeps pressure on Meituan's share and pricing.

    Shows the competitive threat is structural, not fading, even as JD's losses shrink.

  • Record Q2 revenue and return to core profitability Meituan posted record quarterly revenue of RMB104.6 billion, up 14.4%, with adjusted net profit of RMB2.5 billion and core local commerce back in profit. It holds RMB168.3 billion cash and may sell investments worth over RMB70 billion to fund growth and returns.

    The clearest evidence yet that Meituan's core business can make money again.

Latest
▲2▼2

Meituan's subsidy war cools as Q2 profit returns, but Alibaba and JD keep fighting

  • New subsidy rules curb the cash-burning delivery war China's market regulator proposed 10 rules banning prolonged, large-scale subsidy wars in food delivery. Meituan has burned huge cash defending its share, so less forced discounting should improve its long-term profit per order, even though the shares dipped on the day.

    Regulation directly changes the competitive economics that have crushed Meituan's margins.

  • Alibaba bids $1.5B for Pupu, reigniting grocery-delivery rivalry Alibaba offered $1.5 billion for grocery delivery firm Pupu, months after Meituan agreed to buy Dingdong Fresh for $717 million. The bidding war shows rivals are again spending to win market share rather than protect profits, which pressures Meituan to keep investing.

    A direct competitive escalation that could reverse the profit-friendly subsidy truce.

  • JD.com stays aggressive in delivery despite calmer fight JD beat profit estimates as its food delivery losses narrowed, and still targets 30% of the instant-delivery market by year-end, double its starting share. Even with regulators warning against aggressive competition, JD's expansion keeps pressure on Meituan's share and pricing.

    Shows the competitive threat is structural, not fading, even as JD's losses shrink.

  • Record Q2 revenue and return to core profitability Meituan posted record quarterly revenue of RMB104.6 billion, up 14.4%, with adjusted net profit of RMB2.5 billion and core local commerce back in profit. It holds RMB168.3 billion cash and may sell investments worth over RMB70 billion to fund growth and returns.

    The clearest evidence yet that Meituan's core business can make money again.